Video course abdominal ultrasound
Examination of the abdominal vessels – Left renal vein
Author: Prof. Dr. Christoph F. Dietrich ©Falk Foundation e.V., Freiburg. All rights reserved
Please switch on your loudspeakers!
Link to Falk Mediacenter
Latest research in brief:
Bowel
Text:
Feuerstadt P et al, N Engl J Med. 2022;386(3):220–9
Therapy with purified Firmicutes spores (SER-109) reduces the risk of recurrent Clostridioides difficile infection (CDI): In CDI patients with symptom resolution after standard-of-care antibiotics, SER-109 for 3 days was superior to placebo in reducing the risk of recurrent CDI infection in a phase 3 trial. The safety profile of SER-109 was comparable to placebo.
Link to Falk Mediacenter
Text:
Edelman-Klapper H et al, Gastroenterology. 2022;162(2):454–67
Impaired immune response to a SARS-CoV2 mRNA vaccine in patients with inflammatory bowel disease (IBD) treated with anti-TNFα: Antibody responses and functions against viral spike proteins were impaired in IBD patients treated with anti-TNFα as compared to other therapies or healthy controls in a prospective trial from Israel.
Link to Falk Mediacenter
Liver Biliary Tracts
Text:
Tantai X et al, J Hepatol. 2022;76(3):588–99
Sarcopenia as predictor of mortality in cirrhosis: A recent meta-analysis shows that almost 40% of patients with liver cirrhosis are sarcopenic. Sarcopenia significantly increases the risk of mortality in patients with cirrhosis. Thus, adequate nutrition and physical training play an important role in cirrhosis.
Link to Falk Mediacenter
Text:
Koh JH et al, Dig Liver Dis. 2022;54(1):56–62
Efficacy and safety of direct oral anticoagulants (DOAC) in cirrhosis-related portal vein thrombosis: A recent meta-analysis indicates that for the treatment of cirrhosis-associated portal vein thrombosis, the bleeding risk is comparable between DOAC and vitamin K antagonists. However, DOAC were associated with a higher recanalization rate of portal vein thrombosis.
Link to Falk Mediacenter
Text:
Scheiner B et al, J Hepatol. 2022;76(2):353–63
Prognostic score for immunotherapy with atezolizumab plus bevacizumab in hepatocellular carcinoma: The newly developed CRAFITY score, composed of C-reactive protein and alpha-fetoprotein, is associated with survival and radiological response in patients receiving immunotherapy for hepatocellular carcinoma. The score can be helpful in patients counseling but needs prospective validation.
Link to Falk Mediacenter
Esophagus Stomach Duodenum
Text:
Doki Y et al, N Engl J Med. 2022;386(5):449–62
Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma: Both first-line treatment with Nivolumab plus chemotherapy and Nivolumab plus Ipilimumab resulted in significantly longer overall survival than chemotherapy alone in a phase 3 trial.
Link to Falk Mediacenter
Text:
van Munster S et al, Gut. 2022;71(2):265–76
Long-term outcomes after endoscopic treatment for Barrett’s neoplasia with radiofrequency ablation (RFA) ± endoscopic resection (ER): In a national Dutch cohort RFA ± ER was effective and had remarkably low rates of dysplastic recurrence. Moreover, these data support more lenient follow-up intervals and question the value of random biopsies from neo-squamous epithelium and cardia during follow-up.
Link to Falk Mediacenter
Pancreas
No Abstract.
Event
No event
Current Falk literature:
No literature.